WELCOME TO THE NORVIR ANITITRUST LITIGATION WEBSITE 

Norvir is the brand name for ritonavir, which is a drug manufactured by Abbott. Norvir is used as a "booster" for drugs called protease inhibitors that are used to treat HIV and AIDS.

In this lawsuit, the plaintiffs claim that Abbott Laboratories unlawfully raised the price of Norvir to restrict competition. The lawsuit seeks money damages and injunctive relief for consumers and third-party payors ("TPPs") that paid for Norvir.

The Court has said that the lawsuit may go forward on behalf of a Class of consumers and TPPs. The Class consists of all persons or entities throughout the United States and its territories who paid for, or reimbursed another person or entity for Norvir used to boost protease inhibitors. These purchases or reimbursements must have been made after December 3, 2003. Excluded from the Class are Abbott Laboratories and its subsidiaries and affiliates, all government entities (except for government-funded employee benefit funds), and all persons or entities that purchased Norvir: (i) for purposes of resale, or (ii) directly from Abbott Laboratories.

The Notice Plan for the In re Abbot Laboratories Norvir Antitrust Litigation was approved on March 14, 2008.

To help you learn more about the case, we provide some key documents filed with the Court:

• First Amended Class Action Complaint (brought on behalf of consumers)
• Class Action Complaint (brought on behalf of third-party payors)
• Order Granting in Part Plaintiffs' Motion for Class Certification
• Order Granting Plaintiffs' Motion for Approval of Notice Plan, as Modified
• Order Granting in Part Summary Judgment

To understand your rights, please refer to the following notices:

• Third-Party Payor Notice
• Third-Party Payor Summary Notice
• Consumer Notice
• Consumer Summary Notice
• Notificación
• Resumen de Notificación

CONTACT INFORMATION: